Tolvaptan: over-rapid increase in serum sodium and risk of serious neurological events
23rd April 2012
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has warned that treatment with tolvaptan (Samsca, Otsuka) can result in over-rapid correction of hyponatraemia, which can lead to serious neurological events. They give specific advice for healthcare professionals on monitoring of serum sodium and the acceptable rate of rise of serum sodium during treatment and highlight that co-administration of other drugs or fluids with a high sodium content (e.g. normal or hypertonic saline) is not recommended. They also warn that tolvaptan may reduce the effect of vasopressin analogues (e.g. desmopressin) used to control or prevent bleeding.
- Dexamethasone 4mg/mL injection supply problem
- NICE guideline on managing medicines in care homes
- New buprenorphine patch launched in UK
- Die Ausgabe 01/2014 des APM-Newsletter ist erschienen
- Tramadol to be a Schedule 3 CD and temazepam exemptions to be removed
- PCF4 print version now only £25!
- NICE evidence summary of oral ketamine for chronic pain
- First ever Global Atlas identifies unmet need for palliative care
- ACMD recommends reclassifying ketamine
- Phosphate enema new contra-indication